XWELL, Inc. — Cyborg Score 3/10

Challenged
Travel Services

Strategic Profile

Strategic initiatives include rebranding to XWELL, expanding retail products and integrating services across brands to drive non-airport growth and scalability. XWELL highlights a technology and data component through HyperPointe, which it describes as part of the operational and technological core of its biosurveillance and digital healthcare infrastructure, with HyperPointe integrated into existing operations to maintain digital platform and AI capabilities. The company remains early-stage with significant financial challenges, operating at a loss while pursuing growth initiatives.

Cyborg Score Rationale

XWELL generated $26.3M in revenue over the trailing twelve months, retaining a 28.6% gross margin, operating income reached -$15.7M (-59.7% operating margin), and net income was -$17.0M, reflecting a -64.7% net profit margin. With a current ratio of 0.46, short-term liquidity bears monitoring. The company faces going concern doubts despite strategic initiatives.

Top Insights

  • Operational footprint included 25 XpresSpa locations as of March 31, 2026 (16 U.S., 9 international)
  • XpresTest secured and extended CDC bio-surveillance contracts through 2025 and is rolling out multi-pathogen testing with expanded collection sites
  • Serving 1 Million travelers a year across the United States, United Arab Emirates, Holland and Turkey, XWELL is the leading global health and wellness authority for people on the go
  • On April 1, XWELL announced financial results for the full year 2025, reporting total revenue of ~$29.2 million

Named Competitors

  • bioAffinity Technologies — Diagnostics and research services
  • Ispecimen Inc. — Research specimen services
  • Check-Cap Ltd. — Diagnostics and research

Recent Developments

  • (May 2026) Q1 2026 results filed with 25 XpresSpa locations and expanded multi-pathogen testing rollout
  • (April 2026) Full-year 2025 results announced with $29.2 million revenue; CEO Ernst Ezra received 100,000 RSU grant
  • (February 2026) Private equity funding closed at $31 million with 56 investors

Open the full interactive XWELL, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →